FibroGen CEO Thomas Neff dies suddenly as company drives toward first FDA drug approval

Thomas Neff, who led drug developer FibroGen Inc. into San Francisco's nascent biotech cluster a dozen years ago, died unexpectedly this weekend, the company said in a statement Monday. He was 64. The statement did not disclose the cause of death. FibroGen appointed James Schoeneck, most recently CEO of Newark's Depomed Inc. and a nine-year veteran of the FibroGen board, as interim CEO. Neff founded FibroGen in 1993 and in 2006 moved the company up the Peninsula to Mission Bay, where it was…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news